CV Sciences Reports Q3 Growth in Sales and Gross Margins with Plans for PlusHLTH Expansion
CV Sciences (CVSI) reported improved financial performance for the third quarter, highlighted by a sequential increase in sales, gross margins, operating performance, and adjusted EBITDA. The company achieved a significant milestone with gross margins reaching 50% during this period. Looking ahead, management outlined an expansion strategy involving multiple launches of its PlusHLTH brand over the next 12 to 24 months. CEO Joseph Dowling emphasized a strategic focus on building a more efficient and stronger organizational structure to support long-term growth.
Tickers: $CVSI